Edwards Lifesciences (EW) Enters $325M Accelerated Share Repurchase Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Lowe's slashes full-year sales outlook amid DIY spending pressure
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
Edwards Lifesciences Announces $325 Million Accelerated Share Repurchase
February 4, 2016 6:34 PM ESTIRVINE, Calif., Feb. 4, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced today that it has entered into an accelerated share repurchase (ASR) agreement with Morgan Stanley & Co. LLC to repurchase $325 million of Edwards' common stock. This repurchase is part of the Company's... More
